Advances in novel ADCs for HER2-expressing breast cancer

Novel antibody-drug conjugates (ADCs) technologies for management of mBCПодробнее

Overcoming resistance to HER2-directed ADCs in HER2+ breast cancerПодробнее

Resistance to ADCs in breast cancer and novel combination strategiesПодробнее

The ABCs of ADCs: what does the future hold?Подробнее

2022 KU Post San Antonio Review | Metastatic HER2 Positive Breast Cancer: Novel Treatment ApproachesПодробнее

Advances in HER2-Positive Breast Cancer Treatment: Exploring ADCsПодробнее

ADCs for the treatment of HER2-low breast cancerПодробнее

Treatment and Issues For Triple Negative Breast Cancer-May 14, 2020Подробнее

Advances in HER2-Positive Breast Cancer: How ADCs like T-DXd Are Expanding Treatment OptionsПодробнее

TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment ArsenalПодробнее

Emerging strategies to overcome resistance to HER2 ADCs in breast cancerПодробнее

Do ADCs have a future in treating breast cancer?Подробнее

HER2+ Breast Cancer: Evolution of Antibody-Drug ConjugatesПодробнее

Expert Report on advances in the management of HER2-negative and HER2-low advanced breast cancerПодробнее

Combination therapies incorporating ADCs in breast cancerПодробнее

Emerging Antibody-Drug Conjugates in Breast Cancer: An Expert Analysis of Promising TherapiesПодробнее

Antibody Drug Conjugates: The end of chemotherapy | 2023 West Oncology ConferenceПодробнее

A New View of the Spectrum of HER2 Expression and Significance of HER2 Low in Breast CancerПодробнее

Next Generation HER2 Targeted Therapies: Promising Advances in Cancer TreatmentПодробнее

Webinar: Novel Advances in Breast Cancer TreatmentПодробнее

Recommendations for physicians on personalized HER2+ breast cancer treatmentПодробнее